ACADHealthcare · BiotechnologyThe 20 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. hold a median 12-month price target of $33 — +67.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 24 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ACADIA Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACAD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.3% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Needham | Reiterates | Buy | $35 |
| 13 Oct 2026 | UBS | Downgrade | Neutral | $49 → $23 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $37 → $36 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 25 Sept 2026 | BMO Capital | Maintains | Outperform | $36 → $34 |
| 25 Sept 2026 | BMO Capital | Maintains | Outperform | — |
| 25 Sept 2026 | Citizens | Maintains | Market Outperform | — |
| 25 Sept 2026 | Citizens | Maintains | Market Outperform | $36 → $33 |
| 25 Sept 2026 | Deutsche Bank | Maintains | Buy | — |
| 25 Sept 2026 | Deutsche Bank | Maintains | Buy | $38 → $31 |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $37 → $33 |
| 25 Sept 2026 | Needham | Maintains | Buy | — |
| 25 Sept 2026 | Needham | Maintains | Buy | $41 → $35 |
| 24 Sept 2026 | Citigroup | Maintains | Buy | — |
| 24 Sept 2026 | Citigroup | Maintains | Buy | $40 → $33 |
| 24 Sept 2026 | Needham | Reiterates | Buy | — |
| 24 Sept 2026 | Needham | Reiterates | Buy | $41 |
| 25 Aug 2026 | Citigroup | Maintains | Buy | — |
| 25 Aug 2026 | Citigroup | Maintains | Buy | $39 → $40 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ACAD appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, ACADIA Pharmaceuticals, Inc. returned −9.2% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 60% of US stocks
Cheaper than 40% of US stocks
Cheaper than 34% of US stocks
Cheaper than 10% of US stocks
Higher than 64% of US stocks
Higher than 57% of US stocks
Higher than 96% of US stocks
Higher than 68% of US stocks
Higher than 91% of US stocks
Higher than 90% of US stocks
Higher than 69% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ACADIA Pharmaceuticals, Inc. has a market value of $3.4B and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 16.4% year on year.
Net income over the same four quarters: $380.5M, a 33.4% net margin.
Diluted earnings per share, trailing twelve months: $2.22.
Free cash flow in the twelve months to 30 June 2026: $145.6M.
Trailing P/E: 8.8×; forward P/E: 21.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ACADIA Pharmaceuticals, Inc. employs 796 people — $1.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ACADIA Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Acadia Pharmaceuticals said it will report its third-quarter 2026 financial results after U.S. markets close on November 4, 2026. Management will host a conference call and webcast that day at 4:30 p.m. Eastern Time.
Why it matters — ACAD watchers can note the date and time when the company plans to share financial results and discuss them with investors.
Acadia's Nuplazid and Daybue are described as driving revenue growth, with rising demand, new formulations and European expansion cited as opportunities amid growing competition.
Why it matters — These products and potential growth avenues are relevant to ACAD watchers assessing the company's revenue prospects and competitive environment.
Zacks Investment Research named ACAD, alongside AXSM, NBIX and ALKS, among CNS drug stocks to watch for World Mental Health Day. The excerpt cites advances in CNS treatments, product sales, pipeline progress and growth opportunities across the group.
Why it matters — ACAD is included in a roundup highlighting developments in CNS treatments, sales and pipeline opportunities.
Acadia Pharmaceuticals received a patent allowance for Daybue that could extend U.S. protection of the drug to March 2041. The company also reported strong sales growth for trofinetide and gained European approval for the drug.
Why it matters — Extended patent protection for Daybue and its expanding commercial footprint in the U.S. and Europe could strengthen the long-term outlook for ACAD's key trofinetide franchise.
Acadia Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for its U.S. patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome. The patent is expected to issue following completion of standard administrative procedures, extending U.S. patent protections to March 2041.
Why it matters — The allowance extends U.S. patent protection for trofinetide to March 2041, which could strengthen the company's intellectual property position for its Rett syndrome treatment.
The 20 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. have a median 12-month price target of $33, with estimates ranging from $16 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering ACADIA Pharmaceuticals, Inc., 14 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ACADIA Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, ACADIA Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +67.3% from the last close, and Ticker Nerd's factor model ranks ACADIA Pharmaceuticals, Inc. 74 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ACADIA Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACAD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $37 over the next 12 months.
ACADIA Pharmaceuticals, Inc. returned -9.2% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases.
The most recent item we track (Business Wire, 21 Oct 2026): "Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026". Acadia Pharmaceuticals said it will report its third-quarter 2026 financial results after U.S. markets close on November 4, 2026. Management will host a conference call and webcast that day at 4:30 p.m. Eastern Time.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company’s commercial portfolio includes treatments for Parkinson’s disease psychosis and Rett syndrome, reflecting its emphasis on neuropsychiatric and neuro-rare conditions with limited treatment options. Acadia Pharmaceuticals Inc. also maintains a clinical and research pipeline targeting additional unmet needs in neuroscience, including programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, and other rare or underserved patient populations. Based in San Diego, California, the company serves as a specialized player in the healthcare market, combining drug development, regulatory expertise, and commercialization capabilities to support patients, caregivers, and healthcare providers across its therapeutic areas.
CEO Ms. Catherine E. Owen Adams · 796 employees · United States · https://acadia.com
